Cispoly Biotech Completes Nearly RMB 100 Million Series A Financing Led by Haibang Investment, with Probe Capital as Exclusive Financial Advisor

In April 2022, Beijing Origin Cispoly Biotechnology Co., Ltd. (hereinafter referred to as "Cispoly") announced the completion of its Series A financing round, raising nearly RMB 100 million.This round of financing was led by Haibang Investment, with follow-on investment from Qianhai Great Wall Fund. Existing shareholders continued to support Juhé, while Tan Zhen Capital served as the exclusive financial advisor.. The funds from this round of financing will be primarily used for product regulatory approval, pipeline development, clinical trials, and market expansion both domestically and internationally.

Founded in 2020, Juhue Biotech is a high-tech enterprise dedicated to innovative biotechnology and women’s health. Committed to becoming a leader in the early diagnosis of gynecological tumors, the company has developed early detection products for cervical cancer, ovarian cancer, and endometrial cancer, leveraging its proprietary technologies and patent-protected biomarkers, thereby filling a gap in this field.

In 2019, the World Health Organization released the Draft Global Strategy to Accelerate the Elimination of Cervical Cancer (2020–2030), calling for 70% of women aged 35–45 to undergo precise screening and 90% of patients with cervical lesions to receive treatment and care by 2030. Achieving this goal hinges on advances in cervical cancer screening technologies. Traditional HPV and TCT tests, while sensitive, lack sufficient specificity for cervical cancer screening, leading to psychological anxiety and overtreatment among many women and failing to adequately support clinical decision-making. Cispoly addresses this challenge through its independently selected methylation biomarkers, which also effectively differentiate ovarian cancer from endometrial cancer. With user-friendly operation, affordable pricing around RMB 100, and superior performance, Cispoly is driving improvements in the coverage and accessibility of gynecologic oncology screening in China.

Currently, cispolyThree independently developed and manufactured products have entered the clinical approval process.Stage:

I.CisCer^®The rigorous three-step strategy of “retrospective study–prospective study–multicenter cohort study” enables precise clinical detection of cervical cancer, with sensitivity and specificity significantly superior to those of cytology and even histopathological biopsy. This approach can identify lesions hidden in inconspicuous areas and within the endocervical canal, thereby assisting clinical diagnosis and treatment decision-making.

II.Hekouan CisEndo^®Endometrial cancer screening via cervical cell brushing achieves an early detection rate exceeding 92% and facilitates the differentiation between benign, malignant, and borderline tumors. This approach significantly outperforms current clinical guidelines that rely on symptoms and imaging for endometrial cancer evaluation, thereby filling the gap in effective methods for early screening and diagnosis. Furthermore, it serves as an independent, non-invasive screening indicator for women with suspected endometrial cancer or those in outpatient settings, reducing the risk of missed diagnoses associated with hysteroscopy, minimizing the need for repeated hysteroscopic examinations, and delivering significant benefits in early cancer detection.

III.CisOva^®It is a new tool for the differential diagnosis of benign ovarian masses and cysts versus ovarian cancer; it can effectively perform precise detection of methylation variations in circulating tumor DNA (ctDNA) from peripheral blood, achieving a positive detection rate of 86% and a specificity of 95% for ovarian cancer.

All three of the aforementioned products have obtained EU CE certification and may be sold in EU member states and other countries that recognize the CE mark.

Furthermore, Cispoly pioneered China’s first prospective study on DNA methylation for gynecologic tumors—the National Multicenter Cohort Study on Cervical Cancer—as well as the largest domestic multicenter clinical trial for endometrial cancer screening, which has already enrolled over 10,000 patients. Data from the Hegongkang multicenter clinical study were also presented at the EUROGIN (European Research Organization on Genital Infection and Neoplasia) conference, garnering widespread attention both domestically and internationally. Since small-scale studies are prone to bias in real-world settings, early cancer screening products require thorough validation in real-world practice. It is foreseeable that Cispoly’s current research will significantly advance the development of early screening and diagnosis for gynecologic tumors in China.

Dr. Liu Pei, Founder of cispolyStatement: We sincerely appreciate the recognition and strong support from both new and existing shareholders. Cispoly will remain true to its original mission, continuously enriching and developing an innovative pipeline focused on gynecological diseases to address current unmet clinical needs, benefit patients, and contribute to the pharmaceutical industry.

of this round of financingLead Investor: Haibang InvestmentIt is indicated that, with national emphasis and promotion, cervical and breast cancer screening has been incorporated into the basic public health services package, emerging as a new direction for health in the current era. We are highly optimistic about cispoly’s strategy of entering the field of early tumor diagnosis product development through gynecology. The founding team possesses unique insights into this niche sector, accurately grasping clinical needs and efficiently advancing product development and commercial implementation. We aim to support the company in becoming a leading enterprise dedicated to women’s health.

Qianhai Great Wall FundIt was stated that the early screening of tumors represents a blue-ocean market. Cispoly, by focusing on the early screening of gynecological tumors, possesses differentiated competitive advantages. There is strong optimism regarding Cispoly’s product for the early diagnosis and screening of endometrial cancer, Heke’an, which helps women detect endometrial cancer at an early stage and secure valuable time for treatment. It is expected that Heke’an will fill the clinical gap in endometrial cancer screening in the future, and high hopes are placed on its eventual inclusion in clinical guidelines. Meanwhile, the significance of He’gongkang, the product for the early diagnosis and screening of cervical cancer, in preserving fertility among young women is recognized, as it can further enhance the rationality of cervical cancer surgeries. The Cispoly team boasts abundant clinical resources and efficient execution capabilities, with rapid progress in clinical development. There is an expectation for the early approval and market launch of its products to benefit women widely.

Zhang Fang, Executive Director of Probes CapitalStatement: Cispoly is a biotechnology enterprise driven by innovative technology. In the field of early diagnosis and screening for gynecological tumors, it has filled the gap in domestic early diagnostic products for cervical cancer, ovarian cancer, and endometrial cancer with its proprietary technologies and biomarkers. The founder, Liu Pei, and the core team possess strong capabilities in research and development, project management, and execution. It took only one and a half years from the company's establishment to the submission of its core product, Hegongkang, for registration. With the joint support of both new and existing shareholders, the company is poised to rapidly grow into a landmark enterprise in the field of early screening and diagnosis for gynecological tumors.

Haibang Investment was established in 2011 and initiated the establishment of China’s first venture capital fund themed around “entrepreneurship by returnees.” Adhering to a core focus on “technology and talent,” the company primarily concentrates on three major sectors: life and health, digital economy, new materials, and high-end manufacturing. It prioritizes early- to mid-stage projects founded by high-level talents, achieving positive results in promoting the aggregation of high-end talents, supporting their entrepreneurial and innovative endeavors, and facilitating the entry of talent-led enterprises into the capital markets. Haibang Investment has cumulatively established 15 talent-focused funds and multiple specialized funds, with paid-in managed capital exceeding RMB 5 billion. Its funds have invested in over 110 companies, with total investment amounts surpassing RMB 4 billion. Among these portfolio companies, 19 have achieved IPOs or listings through mergers and acquisitions, and more than 20 have been recognized as “unicorn” enterprises. In the life and health sector, Haibang Investment made early-stage investments that nurtured listed companies such as New Horizon Health, GuiChuang TongQiao (Great River Medical), Aotai Biotechnology, and MicroTech Medical.

Qianhai Great Wall Fund Management (Shenzhen) Co., Ltd. was established in July 2015. Upholding the philosophy of strengthening the nation through science and technology, the company has meticulously built an investor team with exceptional expertise and a rigorous work ethic, all of whom are leading figures in the venture capital industry. The company focuses on “early-to-mid-stage investments, hard-tech innovations, domestic substitution, and specialized fields,” adhering to the value concept of distinctive investment. It follows the investment logic of “broad tracks, full-chain coverage, selecting industry leaders, and people-centric approach,” while maintaining a consistent focus on specialized sectors such as biomedicine and semiconductors.

Founded in 2017, Probe Capital is a boutique investment bank specializing in healthcare and life sciences. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. The founding team hails from leading private equity firms, financial advisory agencies, management consulting companies, and vertical healthcare media outlets. Since its inception, Probe Capital has consistently completed double-digit private financing and M&A transactions annually, with cumulative transaction values exceeding RMB 10 billion. In terms of value-added services for enterprises, the Probe Capital team boasts extensive industry expertise. In 2020, the Probe New Healthcare Fund was established and has since invested in more than ten leading companies within the sector.